Skip to main content

Table 3 Comparison of the characteristics of patients who underwent transfusion and those who did not undergo transfusion with data reported for the whole study series and for one-to-one score-matched pair

From: Impact of low skeletal muscle mass index and perioperative blood transfusion on the prognosis for HCC following curative resection

  Whole study series   Propensity score-matched series  
All patients
(n = 139)
Transfusion
(n = 22)
Non-transfusion (n = 117) P-value All patients
(n = 40)
Transfusion
(n = 20)
Non-transfusion (n = 20) P-value
Male sex 110 (79%) 18 (82%) 92 (79%) 1.000 31 (78%) 16 (80%) 15 (75%) 1.000
Age (years) ≥70 88 (63%) 16 (73%) 72 (62%) 0.348 27 (68%) 15 (75%) 12 (60%) 0.501
BMI (kg/m2) ≥25.0 34 (25%) 4 (18%) 30 (26%) 0.593 10 (25%) 4 (20%) 6 (30%) 0.716
HBV 27 (19%) 3 (14%) 24 (21%) 0.568 5 (13%) 3 (15%) 2 (10%) 1.000
HCV 70 (50%) 12 (55%) 58 (50%) 0.817 20 (50%) 10 (50%) 10 (50%) 1.000
DM 29 (21%) 2 (9%) 27 (23%) 0.165 7 (18%) 2 (10%) 5 (25%) 0.407
NLR 13 (9%) 1 (5%) 12 (10%) 0.481 4 (10%) 1 (5%) 2 (10%) 1.000
PNI 11 (8%) 5 (23%) 6 (5%) 0.015 7 (18%) 5 (25%) 2 (10%) 0.407
GPS ≥1 24 (17%) 7 (32%) 17 (15%) 0.065 13 (33%) 6 (30%) 7 (35%) 1.000
Hb (g/dL) 14.1 (9.4–18.2) 13.5 (9.4–17.8) 14.1 (9.4–18.2) 0.016 13.4 (9.4–17.8) 13.7 (9.4–17.8) 13.2 (9.4–15.3) 0.490
PLT (×104/μL) < 14 45 (32%) 8 (36%) 37 (32%) 0.804 13 (33%) 7 (35%) 6 (30%) 1.000
PT (%) < 70 14 (10%) 1 (5%) 13 (11%) 0.698 2 (5%) 1 (5%) 1 (5%) 1.000
T-Bil (mg/dL) ≥1 29 (21%) 4 (14%) 25 (21%) 0.495 6 (15%) 3 (15%) 3 (15%) 1.000
AST (U/L) ≥ 38 57 (41%) 11 (50%) 46 (39%) 0.357 19 (48%) 11 (55%) 8 (40%) 0.527
ALT (U/L) ≥42 41 (30%) 7 (32%) 34 (29%) 0.802 16 (40%) 7 (35%) 9 (45%) 0.748
ChE (g/dL) < 100 3 (2%) 1 (5%) 2 (2%) 0.406 2 (5%) 1 (5%) 1 (5%) 1.000
Alb (g/dL) < 4 63 (45%) 12 (55%) 51 (44%) 0.361 26 (65%) 10 (50%) 16 (80%) 0.096
ICGR15 (%) ≥ 10 93 (67%) 18 (82%) 75 (64%) 0.059 33 (83%) 18 (90%) 15 (75%) 0.407
AFP (ng/mL) ≥ 10 68 (49%) 15 (68%) 53 (45%) 0.102 24 (60%) 13 (65%) 11 (55%) 0.748
PIVKA-II (mAU/mL) ≥ 40 96 (69%) 21 (96%) 75 (64%) 0.004 35 (88%) 19 (95%) 16 (80%) 0.342
Tumor diameter > 2 cm 112 (81%) 20 (91%) 92 (79%) 0.249 37 (93%) 18 (90%) 19 (95%) 1.000
Tumor number 1 (1–5) 1 (1–5) 1 (1–3) 0.963 1 (1–3) 1 (1–3) 1 (1–3) 0.495
Poor differentiation 20 (14%) 3 (14%) 17 (15%) 1.000 4 (10%) 3 (15%) 1 (5%) 0.605
IM (+) 19 (6%) 4 (18%) 15 (13%) 0.738 4 (10%) 2 (10%) 2 (10%) 1.000
Operation time (min) 303 (66–591) 383 (210–591) 282 (66–582) < 0.001 374 (127–591) 383 (210–591) 348 (127–582) 0.461
Intraoperative blood loss (g) 506 (0–6055) 820 (250–6055) 230 (0–2467) < 0.001 500 (40–6055) 820 (250–6055) 450 (40–1181) 0.002
Hospital stay (days) 22 (5–100) 20 (11–80) 17 (5–100) 0.058 20 (11–81) 20 (11–88) 20 (15–81) 0.820
  1. Variables in bold are statistically significant (P<0.05). Continuous variables are expressed as medians (range). Qualitative variables are expressed as numbers (%). Abbreviations: BMI, Hb; hemoglobin, Body mass index; HBV, hepatitis type B; HCV, hepatitis type C, DM, diabetes mellitus; NLR, neutrophil-to-lymphocyte ratio; PNI, prognostic nutritional index; GPS, Glasgow prognostic score; PLT, platelets; PT, prothrombin time; T-Bil, total-bilirubin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ChE, cholinesterase; Alb, albumin; ICGR15, indocyanine green retention15; AFP, α-fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonist-II; IM, intrahepatic metastasis